Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.

Trial Profile

Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
    • 21 Jul 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
    • 30 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top